{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.4","upperLimit":"63.0","value":"53.3"},{"groupId":"OG001","lowerLimit":"40.3","upperLimit":"68.9","value":"54.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"Safety Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants in the Main Cohort and the Safety Expansion Cohort","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Partial Remission (PR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}